Access
To read this story in full you will need to login or make a payment (see right).
News and Views
Nature Medicine 13, 25 - 26 (2007)
doi:10.1038/nm0107-25
Bone-breaking cancer treatment
G David Roodman1
- The author is in the Center for Bone Biology at the University of Pittsburgh Medical Center and the Myeloma Program of the University of Pittsburgh Cancer Institute, VA Pittsburgh Healthcare System, R & D 151U, University Drive C, Pittsburgh, Pennsylvania 15240, USA. e-mail: roodmangd@upmc.edu
Abstract
A drug used to counteract low white blood cell counts in individuals with breast cancer may also be inducing bone metastases (pages 26–27).
Patients with a variety of tumors, including those with breast cancer, are often treated with granulocyte–monocyte colony stimulating factor (GM-CSF), a cytokine that increases white cell counts. GM-CSF stimulates the proliferation and differentiation of hematopoietic precursors, thereby replenishing blood cells ravaged by chemotherapy1.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSFNature Medicine Article (01 Jan 2007)
NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSFNature Medicine Article (01 Jan 2007)
NF-κB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSFNature Medicine Article
See all 6 matches for Research